Craft

Adicet Bio

Stock Price

$1.4

2024-10-29

Market Capitalization

$116.2 M

2024-10-29

Revenue

$25 M

FY, 2022

Adicet Bio Summary

Company Summary

Overview
Adicet Bio is a biotechnology company that develops therapies for cancer diseases. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) for selective tumor targeting and to enhance the immune response. The company also develops proprietary cell platform processes to activate, engineer, and expand gamma delta T cells.
Type
Public
Status
Active
Founded
2016
HQ
Redwood City, CA, US | view all locations
Website
http://www.adicetbio.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Francesco Galimi

    Francesco Galimi, Chief Medical Officer

  • Blake Aftab

    Blake Aftab, Chief Scientific Officer

  • Nick Harvey

    Nick Harvey, Chief Financial Officer

  • Aya Jakobovits

    Aya Jakobovits, Founder & Director

Operating MetricsView all

Patients

1K

FY, 2021

Product Candidates

3
25.0%

FY, 2023

LocationsView all

2 locations detected

  • Redwood City, CA HQ

    United States

    1000 Bridge Parkway

  • Boston, MA

    United States

    131 Dartmouth Street, 3rd Floor

Adicet Bio Financials

Summary Financials

Net income (FY, 2025)
($116.8M)
Cash (FY, 2025)
$38.9M
EBIT (FY, 2025)
($122.1M)
Enterprise value
$91.7M

Footer menu